A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Phase 2

Terminated

• Conditions: Heart Failure; Heart Failure With Preserved Ejection Fraction
• Interventions: Drug: Placebo; Drug: LY3540378

• Registration Number: NCT05592275
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-10-20
• Study First Submitted QC: 2022-10-20
• Study First Posted: 2022-10-24
• Study Start: 2023-02-03
• Primary Completion: 2025-01-22
• Study Completion: 2025-01-22
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-10
• Last Update Posted: 2025-02-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 335

Inclusion Criteria

• Experienced an index event, defined as a recent hospitalization for HF requiring ≥1 bolus doses of intravenous diuretics or an out- of- hospital encounter (for example, Emergency Room, clinic visit, infusion clinic, etc.) for HF requiring ≥1 bolus doses of intravenous diuretics.

• Documented LVEF of ≥50% within 12 months prior to screening; as measured by echocardiography, radionuclide ventriculography, invasive angiography, magnetic resonance imaging (MRI), or computerized tomograph (CT).

• Evidence of documentation of LVEF of ≥50% may also include participant medical records, discharge notes or a referral letter from the participant's physician or referring physician that details the participant's medical history.

• Had evidence of clinical HF syndrome consisting of hospitalization for worsening heart failure (WHF) with intravascular volume overload (the index event), as determined by the investigator, based on appropriate supportive documentation at randomization, and defined by ≥2 of the following:

  • dyspnea
  • jugular venous distention
  • pitting edema in lower extremities (>1+)
  • ascites
  • pulmonary congestion on chest X-ray
  • pulmonary rales AND participant received treatment with IV diuretics.

OR

• Treatment for an urgent visit outside of of being hospitalized with WHF and intravascular volume overload (the index visit) requiring treatment with IV diuretics (defined as ≥2 IV doses) such as in the outpatient setting/emergency room/observation unit/infusion clinic with a clinical response within the past 2 weeks prior to randomization. Urgent visit is defined as an unplanned visit for HF defined by ≥2 of the following:

  • dyspnea
  • jugular venous distention
  • pitting edema in lower extremities (>1+)
  • ascites
  • pulmonary rales on lung examination.

• NT-proBNP (>300 [sinus rhythm] or 600 pg/mL [atrial fibrillation or atrial flutter] OR BNP (>100 [sinus rhythm] or 200 pg/mL [atrial fibrillation or atrial flutter]) at screening.

• eGFR of >20 mL/min/1.73 m² at V1 (screening; determined by local laboratory), derived from serum creatinine values, age, and sex based on the CKD-EPI equation.

Exclusion Criteria

• Prior documentation of low ventricle ejection fraction (LVEF) ≤45% in the past 12 months.
• Have had acute coronary syndrome or percutaneous coronary intervention, coronary artery bypass graft, cardiac mechanical support implantation, within 3 months prior to V2. (randomization), - or any other cardiac surgery planned during the study.
• Have had left ventricular assist device (LVAD) or cardiac transplantation or have cardiac transplantation planned during the study.
• Have hypertrophic cardiomyopathy (obstructive or nonobstructive), restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac sarcoidosis, known amyloid cardiomyopathy, or inherited cardiomyopathy.
• Have a chronic pulmonary/lung disease (COPD), (pulmonary arterial hypertension, etc) as defined by chronic oxygen dependence. Night-time oxygen is not exclusionary.
• Uncorrected thyroid disease.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Participants will be given placebo SC.
LY3540378 Dose 1	LY3540378	Participants will receive LY3540378 subcutaneously (SC).
LY3540378 Dose 2	LY3540378	Participants will receive LY3540378 SC.
LY3540378 Dose 3	LY3540378	Participants will receive LY3540378 SC.

Primary Outcome Measures

Name	Time	Method
Change from Baseline in Left Atrial Reservoir Strain (LARS)	Baseline, Week 26

Secondary Outcome Measures

Name	Time	Method
Change from Baseline in cystatin-C	Baseline, Week 26
Change from Baseline in Log-transformed N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)	Baseline, Week 26
Change from Baseline in Left Atrial End-Diastolic Volume Index (LAEDVI)	Baseline, Week 26
Change from Baseline Left Atrial End-Systolic Volume Index (LAESVI)	Baseline, Week 26
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)	Baseline, Week 26	eGFR calculated by creatinine and cystatin C
Change from Baseline in Serum Creatinine	Baseline, Week 26

Trial Locations

Locations (136)

Pima Heart; 🇺🇸 Tucson, Arizona, United States

Valley Clinical Trials, Inc.; 🇺🇸 Northridge, California, United States

University of California Irvine Medical Center; 🇺🇸 Orange, California, United States

Pasadena Clinical Research; 🇺🇸 Pasadena, California, United States

Velocity Clinical Research, Coastal Heart Medical Group; 🇺🇸 Santa Ana, California, United States

Excel Medical Clinical Trials; 🇺🇸 Boca Raton, Florida, United States

Infinite Clinical Research; 🇺🇸 Miami, Florida, United States

South Florida Research Solutions - North Flamingo Road; 🇺🇸 Pembroke Pines, Florida, United States

University Medical Center New Orleans; 🇺🇸 New Orleans, Louisiana, United States

Boston Medical Center; 🇺🇸 Boston, Massachusetts, United States

Scroll for more (126 remaining)